Lurbinectedin + Durvalumab
Phase 2Recruiting 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Extensive-stage Small-cell Lung Cancer
Conditions
Extensive-stage Small-cell Lung Cancer
Trial Timeline
Apr 25, 2026 → Apr 30, 2028
NCT ID
NCT07459634About Lurbinectedin + Durvalumab
Lurbinectedin + Durvalumab is a phase 2 stage product being developed by Jazz Pharmaceuticals for Extensive-stage Small-cell Lung Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07459634. Target conditions include Extensive-stage Small-cell Lung Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07459634 | Phase 2 | Recruiting |
Competing Products
20 competing products in Extensive-stage Small-cell Lung Cancer